Aptevo Therapeutics Reports Clinical Milestone for Mipletamig Combination Therapy in AML Patients

Article summary

Aptevo Therapeutics announced that 21% of frontline acute myeloid leukemia (AML) patients in a clinical study were able to advance to potentially curative stem cell transplants following treatment with mipletamig in combination with venetoclax and azacitidine.